Trial Profile
An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Sponsors Cynapsus Therapeutics; Sunovion Pharmaceuticals
- 11 Nov 2022 Status changed from active, no longer recruiting to completed.
- 07 Nov 2022 Planned End Date changed from 8 Nov 2022 to 30 Nov 2022.
- 07 Nov 2022 Planned primary completion date changed from 8 Nov 2022 to 30 Nov 2022.